BRIEF published on 08/28/2024 at 13:05, 1 year 5 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 5 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
BRIEF published on 08/21/2024 at 13:05, 1 year 5 months ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 5 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 1 year 5 months ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 1 year 5 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 5 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 7 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 1 year 7 months ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
Published on 02/11/2026 at 14:35, 6 hours 29 minutes ago Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
Published on 02/11/2026 at 14:30, 6 hours 34 minutes ago Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch
Published on 02/11/2026 at 14:00, 7 hours 4 minutes ago Organto Foods Inc. Expands Scalable and Flexible Logistics Platform to Support 2026 Growth
Published on 02/11/2026 at 14:00, 7 hours 4 minutes ago PPX Mining Provides Operational and Corporate Update
Published on 02/11/2026 at 14:00, 7 hours 4 minutes ago Meta Critical Minerals Engages Quad Consulting Group to Advance Table Mountain Silica Project Development Strategy
Published on 02/11/2026 at 19:52, 1 hour 12 minutes ago LR Health & Beauty SE lays foundation for positive future business performance with new financing structure
Published on 02/11/2026 at 19:50, 1 hour 14 minutes ago EQS-Adhoc: LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND ...
Published on 02/11/2026 at 18:31, 2 hours 33 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/11/2026 at 18:00, 3 hours 4 minutes ago Private Equity Holding AG: Net Asset Value as of January 31, 2026
Published on 02/11/2026 at 17:45, 3 hours 19 minutes ago Infotel : Stake held in AeroEx. A publisher of digital compliance and safety solutions for the aerospace industry.
Published on 02/11/2026 at 17:45, 3 hours 19 minutes ago Infotel : Prise de participation dans AeroEx éditeur de solutions digitales de conformité et de sécurité pour l’industrie aéronautique.
Published on 02/11/2026 at 11:25, 9 hours 39 minutes ago Innelec : Mise à disposition du rapport financier semestriel 2025-26
Published on 02/11/2026 at 08:00, 13 hours 4 minutes ago Imerys-press-release French State acquisition stake Emili Lithium
Published on 02/11/2026 at 08:00, 13 hours 4 minutes ago Imerys-communique-de-presse prise participation Etat Français Projet lithium Emili
